Jacobs & Co. CA Purchases 1,473 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Jacobs & Co. CA grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,206 shares of the medical research company’s stock after acquiring an additional 1,473 shares during the period. Jacobs & Co. CA’s holdings in Thermo Fisher Scientific were worth $7,910,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. CCM Investment Advisers LLC grew its position in shares of Thermo Fisher Scientific by 9.7% during the 4th quarter. CCM Investment Advisers LLC now owns 31,921 shares of the medical research company’s stock valued at $16,606,000 after acquiring an additional 2,822 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 0.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 126,603 shares of the medical research company’s stock valued at $65,863,000 after acquiring an additional 887 shares during the period. Hudson Valley Investment Advisors Inc. ADV grew its position in shares of Thermo Fisher Scientific by 1.3% during the 4th quarter. Hudson Valley Investment Advisors Inc. ADV now owns 20,331 shares of the medical research company’s stock valued at $10,577,000 after acquiring an additional 268 shares during the period. Legacy Private Trust Co. grew its position in shares of Thermo Fisher Scientific by 1.8% during the 4th quarter. Legacy Private Trust Co. now owns 11,912 shares of the medical research company’s stock valued at $6,197,000 after acquiring an additional 205 shares during the period. Finally, First Hawaiian Bank grew its position in shares of Thermo Fisher Scientific by 3.0% during the 4th quarter. First Hawaiian Bank now owns 4,158 shares of the medical research company’s stock valued at $2,163,000 after acquiring an additional 122 shares during the period. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. The trade was a 13.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,150 shares of company stock worth $25,954,465 over the last 90 days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Up 0.3 %

Shares of TMO stock traded up $1.78 during mid-day trading on Friday, reaching $546.71. The stock had a trading volume of 2,001,454 shares, compared to its average volume of 1,826,390. The stock’s 50-day moving average price is $530.21 and its two-hundred day moving average price is $568.07. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The firm has a market capitalization of $209.12 billion, a PE ratio of 34.28, a price-to-earnings-growth ratio of 3.54 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same quarter in the previous year, the company earned $5.69 earnings per share. The company’s revenue for the quarter was up .2% compared to the same quarter last year. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a stock repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on TMO shares. Bank of America dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a research note on Friday. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $650.52.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.